Publication In Focus: CHRYSALIS study
NSCLC is the most common type of lung cancer. Mutations in the EGFR gene have been identified as being one of the most common causes of NSCLC. Patients with this type of mutation are difficult to treat or do not experience treatment response with commonly used therapies that target this gene. CHRYSALIS was a Phase I clinical study that evaluated amivantamab as a medicinal treatment for NSCLC patients.
This Publication In Focus describes study cohort D of the CHRYSALIS study, which tested the effects of amivantamab in patients with NSCLC with EGFR ex20ins mutations. Start off by gaining a visual snapshot of the CHRYSALIS study design and its key outcomes in the infographic, next view the explanatory video to explore key takeaways from the trial. Finally, make sure to share the core Plain Language Summary of Publication, which helps patients, their family members and caregivers understand the article better.
FEATURES
The CHRYSALIS study design infographic
EGFR mutations are one of the most common causes of NSCLC tumors. Dive into the CHRYSALIS study with our informative infographic. View the full infographic here >>>.
Check out the original journal article published in Journal of Clinical Oncology, which reports findings from the Phase I CHRYSALIS study.
Plain language summary of a group of patients in the CHRYSALIS study
Read the Plain Language Summary for the above journal article, which is specifically designed to be read by patient and non-specialist audiences to help them to understand the research presented.
Video: a Plain Language Summary of results from the CHRYSALIS study
In this animated video, several experts in the field guide viewers through the key takeaways of the CHRYSALIS study. View the full video here >>>.
In association with Janssen OncologyÂ